Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driverGlobeNewsWire • 03/29/22
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularisGlobeNewsWire • 03/26/22
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo NodularisPRNewsWire • 03/26/22
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer StudyZacks Investment Research • 03/09/22
WHO Backs Merck's Antiviral Pill For High-Risk Covid Patients But Finds Regeneron's Antibody Cocktail ‘Ineffective' Against OmicronForbes • 03/03/22
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinPRNewsWire • 02/28/22
Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic EsophagitisPRNewsWire • 02/26/22
Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous UrticariaPRNewsWire • 02/26/22
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 programGlobeNewsWire • 02/18/22
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 ProgramPRNewsWire • 02/18/22
Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis MeetingPRNewsWire • 02/11/22